12/10/2025

Provepharm plans to launch two new and innovative dyes as early as 2026 - to support the rise in precision surgery and minimally invasive fluorescence-guided robotic surgery

Company is refocusing efforts on innovation and R&D, which have driven growth and success for last 25 years

Strategic partnership with Sagent Pharmaceuticals will allow for distribution of its products in US

Marseille, France, December 10, 2025 – Provepharm, an international pharmaceutical company, today announces its strategic and operational repositioning towards the design, production and supply of innovative dyes for surgical use, particularly in the field of fluorescence-guided surgery.

The company is optimizing its business model to ramp up its growth in the US and other international markets, capitalizing on its renowned in-house expertise and several strategic partnerships.

In the US, Provepharm has opted to partner with Sagent Pharmaceuticals, a leading player in America for injectable and generic products. Sagent will be responsible for distributing Bludigo® (an injectable indigo carmine recently approved by the FDA), along with two new diagnostic dyes scheduled for launch as early as 2026. This alliance will enable the accelerated growth of Provepharm’s high-quality dyes, thanks to the support of a partner with a high degree of market expertise, in-depth knowledge of the customer base and significant commercial resources.

Provepharm also plans to market its two new dyes internationally, via its distributor network, with initial launches taking place in 2026. The aim of these innovations is to meet surgeons’ growing needs in terms of precision medicine and minimally invasive surgery, for more efficient patient care. At the same time, the company is making targeted disinvestments in non-strategic business activities.

“By 2030, our ambition is to be offering an unparalleled range of dyes and to continue innovating to develop their use,” said Hélène Thomas, deputy CEO of Provepharm.

Provepharm will leverage its R&D and scientific know-how to create new, leading-edge medical dyes to support precision surgery. It will also target new growth opportunities via its scientific platform dedicated to fluorescence, which the company plans to use to offer increasingly selective next-generation dyes, known as ‘Smart Dyes’, patented and registered as proprietary medicinal products.

“With this move, it’s back to basics at Provepharm, focusing on what drove our success: setting, and continuing to raise, visualization standards, by concentrating on the purity, stability and use of our products,” said Michel Feraud, chairman and founder of Provepharm.  

The market for medical dye solutions is showing sustained performance, as evidenced by the growing use of indocyanine green and reference dyes such as methylene blue and indigo carmine. It represents more than 8 million units per year (IQVIA, MAT October 2025). This trend is accelerating with the rise in the number of complex surgical procedures, especially in oncology, and the increasingly frequent use of imaging systems and fluorescence-guided surgery in hospital settings.

Advisors
Rothschild & Co acted as financial advisor to Provepharm in structuring and negotiating its commercial partnership with Sagent Pharmaceuticals.

About Sagent Pharmaceuticals
Sagent Pharmaceuticals, founded in 2006, is a leading provider of generic and specialty pharmaceuticals. Sagent’s portfolio of over 100 products offers flexibility across diverse therapeutic categories, formulations and packaging configurations including vials, syringes, premix bags and ophthalmic solutions.  Sagent’s global network of partners with rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, enables its extensive and rapidly expanding pharmaceutical product portfolio, fulfilling the evolving needs of patients.
Discover Pharmaceutical Excellence: visit www.sagentpharma.com

About Provepharm
Provepharm is a pharmaceutical company specializing in the development of high-quality, effective, and ready-to-use dyes designed to enable more precise, more efficient, and less invasive surgical procedures. With over 25 years of expertise in organic chemistry and rigorous scientific and industrial standards, the company develops innovative, high-precision solutions that elevate surgical practice. Provepharm is shaping the future of visualization in the operating room, supported by a strong international partner network and a commercial presence in more than 30 countries. This unique positioning is driven by a committed team, based primarily in Marseille - France, dedicated to advancing both current and future medical practices for the benefit of surgeons and patients.   
www.provepharm.com

Media and analysts contact
Andrew Lloyd & Associates
Céline Gonzalez / Juliette Schmitt
celine@ala.associates / juliette@ala.associates
+44 1273 952 481

Corporate Contact Provepharm
Mary ACARD DUYCK / Corporate Communication Department
mary.acard-duyck@provepharm.com
+33 7 65 15 47 33
 

12/20/2024

Provepharm wishes you a very happy new year! The entire Provepharm team wishes you health, happiness, and success in both your professional and personal endeavors. We would also like to thank all our clients, partners, and employees for their continued trust. Discover our New Year's greetings! 

09/10/2024

On September 19 and 20, the AFC congress will be held, this year dedicated to surgical emergencies. Provepharm is partnering this event for the 1st time, with a booth (n°11) and the organization of a symposium presented by Pr Rouprêt and Pr Lefèvre. The symposium will focus on the management of ureteral lesions during complex visceral surgery.

Over the 2 days, Provepharm's sales, marketing and medical teams will be delighted to discuss the importance of dyes in the surgical management of patients.

09/09/2024

Blumyne™ provides healthcare professionals and hospitals with new, cost-efficient alternative indigo carmine dye for pelvic and abdominal surgery

Marseille, France, September 9, 2024 - Provepharm, a leading international pharmaceutical company specialising in medical dyes and antidotes, today announces the commercial launch of the licensed medicine Blumyne™ 40 mg/5 mL, solution for injection on to the UK market. This indigo carmine (indigotine) dye is a diagnostic agent indicated for the intra-operative detection of suspected ureteral injuries during abdominal and pelvic surgery. 

With only one indigo carmine dye currently licensed as a medicine for surgical use in the UK, the commercial launch of Blumyne™ (40mg/5ml) gives healthcare professionals a new, cost-efficient, therapeutic alternative. By selecting Provepharm, providers gain access to support from an independent company recognised as an expert in the surgical and endoscopic dye market. The opening of the UK affiliate in November 2023 ensures a direct line of customer assistance. 

“I am thrilled to lead the national launch of Blumyne™; much welcomed on the UK market. Provepharm’s years of expertise in the surgical dye market positions the company as a trusted supplier for UK healthcare providers,” said Tim Whelan, UK country manager at Provepharm and head of UK operations. “At Provepharm, we act to improve life and we aim to continue expanding the range of dyes available on the market to provide patients and healthcare professionals with a wider range of therapeutic solutions.” 

Provepharm will continue to develop its range of dyes to cover surgical needs and reinforce knowledge on the benefits of dyes in clinical practice. 

About Provepharm – Act to improve life 
An independent, international specialty pharmaceutical company, Provepharm leverages the potential of well-known molecules to develop innovative solutions that satisfy hospital’s unmet critical needs and help improve patients' lives. Provepharm develops, manufactures and markets a range of hospital products such as antidotes, and endoscopic and surgical dyes. Working closely with healthcare professionals, Provepharm is committed to developing specific services aimed at helping them enhance clinical practices. With a team of over 160 professionals and offices in France, the US and UK, the company markets its products in over 25 countries worldwide and devotes between 20% and 25% of its revenues to R&D. 
The company strives every day to have a positive and significant social, societal and environmental impact in the performance of its activities: that’s its raison d’être. In November 2023, Provepharm joined the exclusive club of pioneering B Corp-certified pharmaceutical companies. www.provepharm.com

03/05/2024

Provepharm will attend the EAHP (European Association of Hospital Pharmacists) congress in Bordeaux 20th to 22th of March 2024.

We will be pleased to welcome European hospital pharmacists on PROVEPHARM both # 67 to present our hospital dyes and our services to improve right usage of dyes. Visitors can also take this opportunity to test their knowledge in our endoscopic and surgical dyes usage thanks to our “Color Quiz”.

03/05/2024

Provepharm will attend the EAHP (European Association of Hospital Pharmacists) congress in Bordeaux 20th to 22th of March 2024.

We will be pleased to welcome European hospital pharmacists on PROVEPHARM both # 67 to present our hospital dyes and our services to improve right usage of dyes. Visitors can also take this opportunity to test their knowledge in our endoscopic and surgical dyes usage thanks to our “Color Quiz”.

12/27/2023

All Provepharm employees wish you happy holidays and All the Best for 2024.

Discover our wishes in video!

11/29/2023

Company joins exclusive club of pioneering B Corp-certified pharmaceutical companies

11/08/2023

Opening will enable pharmaceutical company to better provide UK market with direct distribution and client-facing team. UK third direct-selling country for Provepharm, after France and the United States, expanding commercial presence in medical dye and antidote markets
 

August 2024

Since 2022, Provepharm reached an important milestone in its CSR strategy. In this "2023 CSR Impact, new edition " the essential elements of our approach have been grouped together.